# A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT04600778** · PHASE2 · UNKNOWN · sponsor: **GSNOR Therapeutics, Inc.** · enrollment: 108 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **OTHER:** placebo
- **DRUG:** Cavosonstat 5 mg
- **DRUG:** Cavosonstat 10 mg
- **DRUG:** Cavosonstat 25 mg

## Key facts

- **NCT ID:** NCT04600778
- **Lead sponsor:** GSNOR Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-03
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-04-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04600778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04600778, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04600778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*